What's new? Log in Free sign up

Filing search / Centessa Pharmaceuticals plc / "R&D"

Search information

Centessa Pharmaceuticals plc

Companies

"R&D"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

51 results

Newest first Best match first

CNTA Centessa Pharmaceuticals plc

Quarterly report

to benefit from the UK research and development (“R&D”) tax relief program. For accounting periods prior to April 1, 2024 this consisted of two … programs: the Small and Medium-sized Enterprises R&D tax relief program, or SME Program, and, to the extent that our projects are grant funded or relate

13 Aug 24

7:27am

CNTA Centessa Pharmaceuticals plc

Additional proxy soliciting materials

is in preclinical development. Our team We are led by a management team with both subject matter expertise and extensive R&D experience from leading biotech … with the benefits of diversification and scale typically attributed to traditional large R&D organizations. Medicxi formed Centessa with a view

CNTA Centessa Pharmaceuticals plc

Quarterly report

seek to benefit from the UK research and development (“R&D”) tax relief program. For accounting periods prior to April 1, 2024 this consisted of two … programs: the Small and Medium-sized Enterprises R&D tax relief program, or SME Program, and, to the extent that our projects are grant funded or relate

13 May 24

4:32pm

CNTA Centessa Pharmaceuticals plc

Definitive proxy

to 2021, Dr. Saha served as a Senior Vice President of R&D at Bristol Myers Squibb Company, where he led translational medicine across all therapeutic … a consultant for several biotech companies, R&D Strategy Advisor for LianBio and Senior Advisor for McKinsey. Dr. Hukkelhoven joined Bristol Myers Squibb

9 May 24

8:00am

CNTA Centessa Pharmaceuticals plc

Preliminary proxy

to that, from 2017 to 2021, Dr. Saha served as a Senior Vice President of R&D at Bristol Myers Squibb Company, where he led translational medicine … Bioscience, responsible for R&D, Operations, Medical Affairs and Business Development. Prior to joining Abraxis, she served as Executive Vice President

Prospectus supplement for primary offering

dwrh49ff6ysd0 9u94y

Prospectus supplement for primary offering

28 Mar 24

4:44pm

Quarterly report

13 Nov 23

4:22pm

Quarterly report

14 Aug 23

7:18am

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023

Regulation FD Disclosure

Additional proxy soliciting materials

Definitive proxy

15 May 23

8:01am

pi5x wr801l6gizukwlm

Quarterly report

12 May 23

7:14am

2uwvohntaeodi hj

30 Mar 23

7:44am

bb4gy xi4cxi23b4v

Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022

Quarterly report

10 Nov 22

7:09am

Departure of Directors or Certain Officers

1reha szclq4ye4

Regulation FD Disclosure

Prev
1
2
3
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.